. Author manuscript; available in PMC: 2015 Apr 23.

Published in final edited form as: Int J Geriatr Psychiatry. 2008 Jun;23(6):625–631. doi: 10.1002/gps.1951

Table 1.

Demographic and baseline characteristics

Measure	Placebo (n = 19)	Galantamine (n = 19)	Statistic	p
Age (mean [SD])	69.5 (10.3)	62.5 (9.1)	t = 2.20	0.034^*
Gender (% Male)	31.6	36.8	χ² = 0.12	0.732
Race/ethnicity (% White)	84.2	78.9	χ² = 0.18	0.676
Marital Status (% Married)	31.6	22.2	χ² = 2.36	0.308
Education (% with >12 years)	42.1	88.9	χ² = 8.88	0.003^*
Number of prior antidepressant medications (mean [SD])	1.9 (1.2)	2.6 (2.0)	t = −1.34	0.189
Baseline HDRS-24 (mean [SD])^**	30.3 (6.7)	26.4 (4.5)	t = 2.06	0.047^*
Baseline MMSE (mean [SD])^**	27.4 (1.5)	28.0 (2.0)	t = −0.88	0.384
Baseline RBANS total (mean [SD])^**	81.6 (14.6)	90.9 (16.5)	t = −1.82	0.078

HDRS-24 = 24-item Hamilton Depression Rating Scale; MMSE = Mini-Mental Status Examination; RBANS = Repeatable Battery for Neuropsychological Status.

p < .05.

^**

Does not include data from one subject (randomized to placebo) who did not have baseline testing; see text for details.